NCT00432575 - Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE) | Biotech Hunter

Enrollment

810

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Smoking Cessation

Interventions

DRUG

surinabant (SR147778)

oral administration

DRUG

placebo

oral administration

Trial Locations (8)

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva